Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells

Cancer Cell

Volumn 23, Issue 6, 2013, Pages 811-825

  Roesch, Alexander ^a,b   Vultur, Adina ^b   Bogeski, Ivan ^a   Wang, Huan ^b   Zimmermann, KatharinaM ^a   Speicher, David ^b   Körbel, Christina ^a   Laschke, MatthiasW ^a   Gimotty, PhyllisA ^c   Philipp, StephanE ^a   Krause, Elmar ^a   Pätzold, Sylvie ^d   Villanueva, Jessie ^b   Krepler, Clemens ^b   Fukunaga Kalabis, Mizuho ^b   Hoth, Markus ^a   Bastian, BorisC ^e   Vogt, Thomas ^a   Herlyn, Meenhard ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BORTEZOMIB; CISPLATIN; HISTONE DEMETHYLASE; HISTONE H3; OLIGOMYCIN; PHENFORMIN; PROTEIN JARID1B; PROTEIN KDM5B; PROTEIN PLU 1; PROTEOME; ROTENONE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VEMURAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CELL CYCLE; CELL PROLIFERATION; CELL SUBPOPULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEOMICS; RESPIRATORY CHAIN; SENSITIZATION; UPREGULATION;

EID: 84878959237     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.05.003     Document Type: Article

References (34)

1. Appleyard M.V., Murray K.E., Coates P.J., Wullschleger S., Bray S.E., Kernohan N.M., Fleming S., Alessi D.R., Thompson A.M. Phenformin as prophylaxis and therapy in breast cancer xenografts. Br. J. Cancer 2012, 106:1117-1122.
2. Berridge M.V., Herst P.M., Tan A.S. Metabolic flexibility and cell hierarchy in metastatic cancer. Mitochondrion 2010, 10:584-588.
3. Blagosklonny M.V. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 2005, 4:1693-1698.
4. Caro P., Kishan A.U., Norberg E., Stanley I.A., Chapuy B., Ficarro S.B., Polak K., Tondera D., Gounarides J., Yin H., et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 2012, 22:547-560.
5. Charton C., Ulaszewski S., da Silva Vieira M.R., Henoux V., Claisse M.L. Effects of oligomycins on adenosine triphosphatase activity of mitochondria isolated from the yeasts Saccharomyces cerevisiae and Schwanniomyces castellii. Biochem. Biophys. Res. Commun. 2004, 318:67-72.
6. Chen K.G., Valencia J.C., Gillet J.P., Hearing V.J., Gottesman M.M. Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res. 2009, 22:740-749.
7. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
8. Christensen J., Agger K., Cloos P.A., Pasini D., Rose S., Sennels L., Rappsilber J., Hansen K.H., Salcini A.E., Helin K. RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell 2007, 128:1063-1076.
9. Dey B.K., Stalker L., Schnerch A., Bhatia M., Taylor-Papidimitriou J., Wynder C. The histone demethylase KDM5b/JARID1b plays a role in cell fate decisions by blocking terminal differentiation. Mol. Cell. Biol. 2008, 28:5312-5327.
10. Grazette L.P., Boecker W., Matsui T., Semigran M., Force T.L., Hajjar R.J., Rosenzweig A. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 2004, 44:2231-2238.
11. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
12. Hao W., Chang C.P., Tsao C.C., Xu J. Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. J. Biol. Chem. 2010, 285:12647-12654.
13. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
14. Imamura H., Nhat K.P., Togawa H., Saito K., Iino R., Kato-Yamada Y., Nagai T., Noji H. Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proc. Natl. Acad. Sci. USA 2009, 106:15651-15656.
15. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., Emery C.M., Stransky N., Cogdill A.P., Barretina J., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
16. Jose C., Bellance N., Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma?. Biochim. Biophys. Acta 2011, 1807:552-561.
17. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.K., Attar N., Sazegar H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
18. Poulikakos P.I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., Shi H., Atefi M., Titz B., Gabay M.T., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
19. Roesch A., Becker B., Meyer S., Wild P., Hafner C., Landthaler M., Vogt T. Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Mod. Pathol. 2005, 18:1249-1257.
20. Roesch A., Becker B., Schneider-Brachert W., Hagen I., Landthaler M., Vogt T. Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells. J. Invest. Dermatol. 2006, 126:1850-1859.
21. Roesch A., Mueller A.M., Stempfl T., Moehle C., Landthaler M., Vogt T. RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. Int. J. Cancer 2008, 122:1047-1057.
22. Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., Basu D., Gimotty P., Vogt T., Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
23. Scott D.A., Richardson A.D., Filipp F.V., Knutzen C.A., Chiang G.G., Ronai Z.A., Osterman A.L., Smith J.W. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J. Biol. Chem. 2011, 286:42626-42634.
24. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
25. Smalley K.S., Haass N.K., Brafford P.A., Lioni M., Flaherty K.T., Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 2006, 5:1136-1144.
26. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N.Engl. J. Med. 2012, 366:707-714.
27. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
28. Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X., Gimotty P.A., Kee D., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695.
29. Wagle N., Emery C., Berger M.F., Davis M.J., Sawyer A., Pochanard P., Kehoe S.M., Johannessen C.M., Macconaill L.E., Hahn W.C., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 2011, 29:3085-3096.
30. Warburg O., Posener K., Negelein E. Ueber den stoffwechsel der tumoren. Biochem. Z. 1924, 152:319-344.
31. Weinberg F., Hamanaka R., Wheaton W.W., Weinberg S., Joseph J., Lopez M., Kalyanaraman B., Mutlu G.M., Budinger G.R., Chandel N.S. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. USA 2010, 107:8788-8793.
32. White R.M., Cech J., Ratanasirintrawoot S., Lin C.Y., Rahl P.B., Burke C.J., Langdon E., Tomlinson M.L., Mosher J., Kaufman C., et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 2011, 471:518-522.
33. Xia X., Lemieux M.E., Li W., Carroll J.S., Brown M., Liu X.S., Kung A.L. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc. Natl. Acad. Sci. USA 2009, 106:4260-4265.
34. Yamane K., Tateishi K., Klose R.J., Fang J., Fabrizio L.A., Erdjument-Bromage H., Taylor-Papadimitriou J., Tempst P., Zhang Y. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol. Cell 2007, 25:801-812.